Searched for
NOVO NORDISK SALES
India’s GLP-1 boom loses steam as price war, weak retention hit generic weight-loss drug salesInitial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-ex...- Healthium Medtech CEO Anish Bafna steps down, moves to non-executive chairman roleHealthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...
- Bombay HC cancels 'Duphachrit' trademark, rules it deceptively similar to Abbott's 'Dupha' familyThe Bombay High Court has cancelled Thane-based Menschlich Healthcare's trademark 'Duphachrit' in favour of Abbott Product Operations AG. T...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Semaglutide race: Torrent grabs 38% market shareOver a dozen Indian companies have launched generic versions of the GLP1 drug used for diabetes and weight management since the expiry of N...
- Stocks in news: SBI, Titan, Hyundai, BSE, Torrent Pharma, Axis BankIndian markets saw volatile trading on Thursday, closing nearly unchanged despite positive signals. Several companies including SBI, Titan,...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- US Stocks: Eli Lilly raises annual forecasts as GLP-1 drugs fuel growthEli Lilly raised its annual profit and revenue forecasts and posted better-than-expected first quarter on Thursday, on steady demand for it...
- Global Markets | European equities log steep weekly losses with no resolution to MidEast conflictEuropean stocks saw a significant weekly drop Friday. Investors are concerned about growth and inflation due to Middle East conflict disrup...
- Eli Lilly Foundayo weight-loss pill vs Novo Nordisk Wegovy oral obesity treatment tablets: Which medicine is the most prescribed across U.S.?Eli Lilly Foundayo was approved in the U.S. on April 1, with prescriptions accepted immediately on LillyDirect, while shipping started on A...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- NVO stock crashes 14%: Why Novo Nordisk shares are down today? 2026 sales forecast and Eli Lilly competition explainedNVO Novo Nordisk stock today: Novo Nordisk shares tumbled after the drugmaker forecast a sales and profit drop for 2026. This outlook comes...
- HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglut...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Novo Nordisk stock plunges 23% after cutting sales forecast and naming Mike Doustdar as new CEONVO stock today: Novo Nordisk's stock plummeted over 23% following a reduced full-year sales forecast and the announcement of Maziar Mike D...
- Obesity drug maker Novo Nordisk ousts CEO as competition weighsNovo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity d...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
Load More
